Hunan Jiudian Pharmaceutical Co., Ltd. Share Price

Equities

300705

CNE1000034Z6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 26/04/2024 am IST 5-day change 1st Jan Change
36.22 CNY +3.46% Intraday chart for Hunan Jiudian Pharmaceutical Co., Ltd. +4.96% +9.00%

Financials

Sales 2024 * 3.37B 465M 38.8B Sales 2025 * 4.18B 577M 48.12B Capitalization 12.5B 1.73B 144B
Net income 2024 * 502M 69.28M 5.78B Net income 2025 * 649M 89.57M 7.47B EV / Sales 2024 * 3.71 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.99 x
P/E ratio 2024 *
24.9 x
P/E ratio 2025 *
19.2 x
Employees 1,636
Yield 2024 *
0.5%
Yield 2025 *
0.61%
Free-Float 48.72%
More Fundamentals * Assessed data
Dynamic Chart
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd.(XSEC:300705) added to S&P Global BMI Index CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year of 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hunan Jiudian Pharma Wins Nod to Trial Anti-Inflammatory Patch MT
Jiudian Pharma Sees FY22 Profit to Rise Up to 33.7% MT
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022 CI
More news
1 day+3.46%
1 week+4.96%
Current month-3.52%
1 month-1.90%
3 months+18.52%
6 months+42.09%
Current year+9.00%
More quotes
1 week
33.08
Extreme 33.08
36.73
1 month
33.08
Extreme 33.08
38.98
Current year
27.68
Extreme 27.68
39.00
1 year
18.80
Extreme 18.8
39.00
3 years
13.14
Extreme 13.1357
39.00
5 years
6.85
Extreme 6.85
39.00
10 years
4.44
Extreme 4.4429
39.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/03/01
Director of Finance/CFO 60 01/07/01
Director/Board Member 47 01/01/01
Members of the board TitleAgeSince
Chairman 61 01/01/01
Director/Board Member 60 01/01/01
Director/Board Member 57 01/01/01
More insiders
Date Price Change Volume
26/24/26 36.22 +3.46% 5,236,342
25/24/25 35.01 +2.67% 7,675,592
24/24/24 34.1 -1.33% 3,023,474
23/24/23 34.56 -4.24% 4,832,800
22/24/22 36.09 +4.58% 2,584,185

End-of-day quote Shenzhen S.E., April 26, 2024

More quotes
Hunan Jiudian Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of pharmaceutical preparations. The Company’s products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The Company sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.22
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300705 Stock